Clinical Trials
43 trialsCT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
BASECAMP-1
A2 Biotherapeutics Inc.
EVEREST-2
A2 Biotherapeutics Inc.
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
ABILITY-1
Medicenna Therapeutics, Inc.
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
CAR T Cells in Mesothelin Expressing Cancers
University of Pennsylvania
TOASTIT
Mayo Clinic
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
PITHAC
Centre Hospitalier Universitaire Vaudois
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
PIPACRegis
University of Magdeburg
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
Kantonsspital Winterthur KSW
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
HOPE
Wake Forest University Health Sciences
Collecting Tumor Samples From Patients With Gynecological Tumors
GOG Foundation
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Chinese PLA General Hospital
Immunotoxin Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
National Cancer Institute (NCI)